全文获取类型
收费全文 | 10030篇 |
免费 | 571篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 88篇 |
儿科学 | 250篇 |
妇产科学 | 165篇 |
基础医学 | 1881篇 |
口腔科学 | 135篇 |
临床医学 | 878篇 |
内科学 | 1667篇 |
皮肤病学 | 264篇 |
神经病学 | 1353篇 |
特种医学 | 509篇 |
外国民族医学 | 1篇 |
外科学 | 1029篇 |
综合类 | 52篇 |
预防医学 | 565篇 |
眼科学 | 187篇 |
药学 | 785篇 |
中国医学 | 20篇 |
肿瘤学 | 798篇 |
出版年
2023年 | 37篇 |
2022年 | 58篇 |
2021年 | 128篇 |
2020年 | 109篇 |
2019年 | 149篇 |
2018年 | 190篇 |
2017年 | 142篇 |
2016年 | 227篇 |
2015年 | 252篇 |
2014年 | 314篇 |
2013年 | 383篇 |
2012年 | 588篇 |
2011年 | 616篇 |
2010年 | 439篇 |
2009年 | 369篇 |
2008年 | 558篇 |
2007年 | 582篇 |
2006年 | 609篇 |
2005年 | 548篇 |
2004年 | 482篇 |
2003年 | 524篇 |
2002年 | 529篇 |
2001年 | 112篇 |
2000年 | 132篇 |
1999年 | 141篇 |
1998年 | 152篇 |
1997年 | 122篇 |
1996年 | 88篇 |
1995年 | 81篇 |
1994年 | 70篇 |
1993年 | 71篇 |
1992年 | 75篇 |
1991年 | 66篇 |
1990年 | 72篇 |
1989年 | 63篇 |
1988年 | 65篇 |
1987年 | 50篇 |
1985年 | 56篇 |
1984年 | 39篇 |
1983年 | 46篇 |
1982年 | 46篇 |
1981年 | 44篇 |
1980年 | 43篇 |
1979年 | 54篇 |
1978年 | 43篇 |
1977年 | 44篇 |
1976年 | 45篇 |
1955年 | 44篇 |
1954年 | 36篇 |
1932年 | 41篇 |
排序方式: 共有10000条查询结果,搜索用时 236 毫秒
181.
Market research is a popular instrument used by industry tolearn more about the profile and expectations of potential clients.Scientific and professional societies, the European Societyof Medical Oncology (ESMO) included, also need to be acquaintedwith their members characteristicstheir background,working conditions, activities, needs and expectations. Thesewere among the considerations that prompted ESMO to undertakea membership survey. Last year, a questionnaire was designedand sent out by mail to 3457 ESMO members of whom 393 (11.4%)returned the completed files. Although the response rate was 相似文献
182.
Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. 总被引:7,自引:0,他引:7
Wulf Sienel Sebastian Dango Ute Woelfle Alicia Morresi-Hauf Christoph Wagener Jens Brümmer Wolf Mutschler Bernward Passlick Klaus Pantel 《Clinical cancer research》2003,9(6):2260-2266
PURPOSE: Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) has recently been implicated in cancer development and progression. This study was performed to assess whether CEACAM-1 expression in primary tumors is correlated to long-term survival in patients with operable non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN: Primary tumors of 145 consecutive patients with completely resected NSCLC (pT(1-4) pN(0-2) M(0) R(0)) were stained immunohistochemically using the monoclonal anti-CEACAM-1 antibody 4D1/C2. The prognostic relevance of CEACAM-1 expression was evaluated by univariate Kaplan-Meier and multivariate Cox regression analysis. The median follow-up period was 72 months (range, 10-130 months). RESULTS: Normal bronchiolar epithelium present in all sections exhibited no immunostaining. In contrast, 73 tumors (50.4%) showed between 1 and 66% CEACAM-1 positive tumor cells, and 72 tumors (49.6%) exhibited even a higher percentage of positive tumor cells. A high CEACAM-1 expression rate (i.e., >/=66% positive tumor cells) was more frequent in adenocarcinomas than in squamous cell carcinomas (61.9 versus 35.7%, respectively). Multivariate Cox regression analysis demonstrated that CEACAM-1 represents an independent prognosticator for cancer-related survival (P = 0.018; relative risk, 1.8; 95% confidence interval, 1.1-2.8). Subgroup analysis revealed that a high CEACAM-1 expression rate was of significant prognostic impact in pN(1)-pN(2) patients (n = 60; P = 0.024), pT(3)-pT(4) patients (n = 22; P = 0.009), and stage IIa-IIIa patients (n = 69; P = 0.012). CONCLUSIONS: The absence of CEACAM-1 in normal lung tissue and its expression in tumor cells argues against a tumor-suppressive role of CEACAM-1 in NSCLC. The correlation between elevated CEACAM-1 expression and an unfavorable prognosis indicates rather that CEACAM-1 might promote lung cancer progression. 相似文献
183.
Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. 总被引:6,自引:0,他引:6
Katja Ott Holger Vogelsang James Mueller Karen Becker Martina Müller Ulrich Fink J?rg Rüdiger Siewert Heinz H?fler Gisela Keller 《Clinical cancer research》2003,9(6):2307-2315
PURPOSE: The objective of the study was to evaluate microsatellite alterations [microsatellite instability (MSI) and loss of heterozygosity (LOH)] and mutation in the p53 gene in relation to response and patient survival to a cisplatin-based neoadjuvant chemotherapy in gastric cancer. EXPERIMENTAL DESIGN: Fifty-three pretherapeutic gastric carcinoma biopsies were analyzed with 11 microsatellite markers. The entire coding region of the p53 gene (exons 2-11) was analyzed for mutations by denaturing high-pressure liquid chromatography and sequencing. p53 protein expression was evaluated by immunohistochemistry. Patients were treated with a cisplatin-based, neoadjuvant chemotherapy regimen. Therapy response was evaluated by computed tomography scan, endoscopy, and endoluminal ultrasound. The median follow-up of the patients was 45.6 months. RESULTS: p53 mutations were identified in 19 of the 53 (36%) analyzed tumors. No significant association with response or survival was found for p53 mutation or for p53 protein expression. MSI (either high-grade MSI or low-grade MSI) did not show a correlation with response. With respect to LOH, LOH at chromosome 17p13 showed a significant association with therapy response (P = 0.022) but did not reach statistical significance in terms of patient survival. The global LOH rate, expressed as fractional allelic loss (FAL), was assessed, and tumors were classified into tumors with a high (>0.5), medium (>0.25-0.5), and low (0-0.25) FAL value. A statistically significant association of FAL with therapy response was found (P = 0.003), with a high FAL being related to therapy response. The sensitivity, specificity, positive predictive value, and negative predictive value for FAL > 0.5 were 45%, 93%, 82%, and 72%, respectively. CONCLUSIONS: A high level of chromosomal instability (high FAL value) defines a subset of patients who are more likely to benefit from cisplatin-based neoadjuvant chemotherapy. p53 mutation status is not significantly associated with therapy response and is not a useful marker for response prediction. 相似文献
184.
Primo N Lara Paul Frankel Philip C Mack Paul H Gumerlock Irina Galvin Cynthia L Martel Jeff Longmate James H Doroshow Heinz Josef Lenz Derick H M Lau David R Gandara 《Clinical cancer research》2003,9(12):4356-4362
PURPOSE: Tumor hypoxia confers chemotherapy resistance. Tirapazamine is a cytotoxin that selectively targets hypoxic cells and has supra-additive toxicity with platinums and taxanes in preclinical studies. We conducted a Phase I study of tirapazamine, carboplatin, and paclitaxel and assessed potential plasma markers of hypoxia as surrogates for response. EXPERIMENTAL DESIGN: Forty-two patients with advanced solid tumors were treated at four dose levels; parallel dose escalations were carried out in chemotherapy-naive and previously treated subjects. Pre and post-therapy plasma levels of the hypoxia-induced proteins plasminogen activator inhibitor-1 and vascular endothelial growth factor were measured. RESULTS: Three of four chemotherapy-na?ve patients developed dose-limiting toxicities at dose level 4 (grade 3 stomatitis/infection, grade 3 emesis, and grade 4 febrile neutropenia). Four of seven previously treated patients developed dose-limiting toxicities at dose level 3, including one death [grade 3 myalgia, grade 3 infection/grade 4 neutropenia, grade 3 infection/grade 4 neutropenia, and grade 5 infection (death)/grade 4 neutropenia]. Of 38 patients assessable for response, 3 had a complete response, 1 a partial response, 1 an unconfirmed partial response, and 23 had stable disease in at least one evaluation; 10 quickly progressed. One complete responder had normalization of vascular endothelial growth factor and plasminogen activator inhibitor-1 levels. CONCLUSION: Dose levels 3 (carboplatin AUC of 6, 225 mg/m(2) paclitaxel, and 330 mg/m(2) tirapazamine) and 2 (carboplatin AUC 6, 225 mg/m(2) paclitaxel, and 260 mg/m(2) tirapazamine) are the maximum tolerated doses for chemotherapy naive and patients treated previously, respectively. Dose level 3 is the experimental arm of a Phase III Southwest Oncology Group trial (S0003) in advanced non-small cell lung cancer. Potential markers of tumor hypoxia may be useful correlates in studies of hypoxic cytotoxins and are being prospectively investigated in S0003. 相似文献
185.
Datenschutz innerhalb des länderübergreifenden Deutschen Zentralregisters für kindliche Hörstörungen
Zusammenfassung
Das Deutsche Zentralregister für kindliche H?rst?rungen (DZH) verarbeitet bundesweit Daten von verschiedenen audiologischen
Einrichtungen. Die Bew?ltigung der anfallenden Datenmengen, die nachfolgende Datenverwaltung und -analyse erfordern neben
einer differenzierten und kontrollierbaren Verarbeitung ein H?chstma? an Datensicherheit. Vor allem die l?nderübergreifende
Struktur eines Registers erfordert schon bei der Planung engste Zusammenarbeit mit dem zust?ndigen Landesdatenschutzbeauftragten
und auch mit den Landesdatenschutzbeauftragten anderer beteiligter Bundesl?nder. Am Beispiel des DZH wird demonstriert, wie
eine kooperative Zusammenarbeit pragmatisch realisiert werden kann. Besonderheiten bei der Datenerhebung, Datentransfer, Speicherung
und L?schung von Daten, technische Datenschutzma?nahmen, Sicherstellung von Anonymit?t durch Codierungsstrategien, Duplikatsprüfung,
Datentrennung und automatisierte Datenauswertung werden an Beispielen erl?utert.
Eingegangen am 13. August 1997 Angenommen am 18. Dezember 1997 相似文献
186.
Ute Finckh-Krämer Maria-Elisabeth Spormann-Lagodzinski K. Nubel M. Hess M. Gross 《HNO》1998,46(6):598-602
Zusammenfassung
Das Deutsche Zentralregister (DZH) für kindliche H?rst?rungen hat seit 1994 Patientendatens?tze von 1500 Kindern erfa?t und
kann mittlerweile u.a. Aussagen und Ergebnisse zum Diagnosezeitpunkt persistierender kindlicher H?rst?rungen in der Bundesrepublik
Deutschland vorlegen. Nach wie vor ist das mittlere Alter bei der Diagnose persistierender kindlicher H?rst?rungen sehr hoch.
Das Diagnosealter korreliert stark mit dem Grad der H?rst?rung, d.h. an Taubheit grenzende und hochgradige H?rst?rungen werden
deutlich früher diagnostiziert als leichte und mittlere. So werden leichte H?rst?rungen im Durchschnitt erst mit 6;2 Jahren
diagnostiziert, mittlere mit 4;4 Jahren, hochgradige mit 2;5 Jahren und an Taubheit grenzende mit 1;9 Jahren. Dies entspricht
den Ergebnissen bereits vorliegender regionaler deutscher Studien [1–2]. Aus anderen europ?ischen L?nderen sind zumindest
regional deutlich frühere Diagnosezeitpunkte bekannt [3–5]. Bei 36% der im DZH erfa?ten Kinder liegt zwischen dem ersten Verdacht
auf Vorliegen einer persistierenden kindlichen H?rst?rung und der Sicherstellung der Diagnose ein Jahr und mehr.
Eingegangen am 23. Dezember 1997 Angenommen am 16. April 1998 相似文献
187.
188.
Sebastian Roka Michael Fiegl Niklas Zojer Martin Filipits Rudolf Schuster Birgit Steiner Raimund Jakesz Heinz Huber Johannes Drach 《Breast cancer research and treatment》1998,48(2):125-133
Previous work from our laboratory demonstrated aneuploidy for several chromosomes by interphase fluorescence in situ hybridization (FISH) in a high proportion of breast cancer specimens. In the literature, only limited data are available concerning chromosome 8 anomalies in breast cancer. To determine chromosome 8 ploidy status in primary and metastatic specimens from 81 breast cancer patients, FISH analysis with a DNA probe recognizing chromosome 8 centromeres was performed. In all primary tumor specimens (n=30), significant proportions of cells were aneuploid exhibiting gain of chromosome 8 copy numbers; in 75% of effusion specimens previously classified as malignant by cytology and/or FISH for various chromosomes (n=40), cell populations aneuploid for chromosome 8 were detected; effusions previously classified non-malignant (n=11) were diploid in 10 cases, whereas one specimen contained rare hyperdiploid cells. Among these cells complex chromosomal aneuploidy could be demonstrated by two-color FISH, suggesting malignancy. Trisomic and tetrasomic clones were predominant in the majority of samples, but a marked intratumor cytogenetic heterogeneity was observed in most cases. Primary tumors and corresponding positive axillary lymph nodes revealed similar distributions of chromosome 8 copy numbers, analogous to previous findings with other chromosomes. This implies that, by using suitable FISH probes after examination of the respective primary tumor, an efficient search for (micro)metastasis might be feasible. 相似文献
189.
Siostrzonek P Koreny M Delle-Karth G Haumer M Koller-Strametz J Heinz G 《Acta anaesthesiologica Scandinavica》2000,44(4):403-409
BACKGROUND: Treatment with the PDE-III inhibitor milrinone improves hemodynamics in patients with heart failure. We examined whether therapy with milrinone is safe and effective in critically ill patients with catecholamine-dependent heart failure and whether treatment with milrinone facilitates weaning from prolonged catecholamine therapy. METHODS: Twenty adult patients with reduced left ventricular function and prolonged (7+/-4 days) catecholamine therapy in whom attempts at catecholamine weaning had failed were examined. Patients were prospectively randomised either to group A (addition of a fixed dose of 0.5 microg x kg(-1) x min(-1) milrinone to catecholamine therapy) or to group B (continued catecholamine therapy without milrinone). Dobutamine and norepinephrine treatment and fluid intake were titrated according to predefined hemodynamic goals. Hemodynamic parameters, fluid requirements and catecholamine dose were monitored. RESULTS: After 24 h of study treatment goup A showed a significant increase in cardiac index (2.2+/-0.4 1 min(-1) x m(-2) to 2.7+/-0.51 min(-1) x m(-2); P<0.005), a decrease in systemic vascular resistance (1,427+/-609 dyn x s x cm(-5) to 951+/-184 dyn x s x cm(-5); P<0.005), required lower doses of dobutamine (5.9+/-4.2 microg x kg(-1) x min(-1) to 2.2+/-3.3 microg x kg(-1) x min(-1); P<0.02), but showed a tendency for higher vasoconstrictor (0.14+/-0.16 microg x kg(-1) x min(-1) to 0.29+/-0.43 microg x kg(-1) x min(-1); P=n.s.) and fluid requirements (+1,404+/-2,257 ml/24 h to +2,508+/-1,873 ml/ 24 h; P=n.s.). No significant changes occurred in group B. Weaning from catecholamine therapy was more often achieved in group A and more milrinone treated patients were discharged alive from the ICU (80% vs. 30%; P<0.05). CONCLUSIONS: Milrinone improves central hemodynamics and may facilitate weaning from prolonged catecholamine support in critically ill patients with heart failure. Its administration in this subset of critically ill patients is safe, but eventually is associated with additional vasoconstrictor and fluid requirements. 相似文献
190.
Roberto Marchioli Guido Finazzi Raffaele Landolfi Jack Kutti Heinz Gisslinger Carlo Patrono Raphael Marilus Ana Villegas Gianni Tognoni Tiziano Barbui 《Journal of clinical oncology》2005,23(10):2224-2232
PURPOSE: The clinical course of polycythemia vera is often complicated by thrombosis as well as by the possible transition to myeloid metaplasia with myelofibrosis or acute myeloid leukemia. The aim of this study was to assess the rate of these complications in subjects receiving currently recommended treatments. PATIENTS AND METHODS: Overall, 1,638 patients from 12 countries were enrolled onto a large, prospective multicenter project aimed at describing the clinical history of polycythemia vera for the following outcomes: survival, the cumulative rate of cardiovascular death and thrombosis, the cumulative rate of leukemia, myelodysplasia, and myelofibrosis. The mean duration of the disease at entry and the duration of the follow-up were 4.9 and 2.7 years, respectively. RESULTS: The overall mortality rate of 3.7 deaths per 100 persons per year resulted from a moderate risk of cardiovascular death and a high risk of death from noncardiovascular causes (mainly hematologic transformations). Age older than 65 years and a positive history of thrombosis were the most important predictors of cardiovascular events. Antiplatelet therapy, but not cytoreductive treatment, was significantly associated with a lower risk of cardiovascular events. We found a consistent association between age and risk of leukemia, and between duration of the disease with risk of myelofibrosis. CONCLUSION: The European Collaboration on Low-Dose Aspirin in Polycythemia Vera study documents that large international collaborative studies are feasible in this field, in which few epidemiologic data are available. The persistently high mortality rate from hematologic malignancies characterizes the unmet therapeutic need of polycythemic patients and suggests a priority for future studies in this disease. 相似文献